National Drug Procurement Office Reports Serious Defects in Production Line of Centrally Procured Drug Amiodarone Hydrochloride Injection; Production Suspended
On June 9, 2026, the National Organization for Joint Drug Procurement announced that the production line for amiodarone hydrochloride injection, a centrally procured life-saving drug produced by Shandong Beida Gaokua Huatai Pharmaceutical, has serious defects and has been ordered to suspend production.